In addition, cyclin-dependent protein kinase 9 (CDK9) is a druggable target for prostate cancer because CDK9 can not only phosphorylate AR and activate AR transcriptional activity but also target anti-apoptotic proteins [82]. The gene discussed is AR; the disease is Familial prostate cancer.